TEL AVIV, Israel, 22 December 2021 / PRNewswire / – SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage specialty pharmaceutical company focused on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced that its common stock will begin trading today on the Nasdaq Capital Market (“Nasdaq”) under the symbol “SPRC”.

About SciSparc (SPRC):

SciSparc Ltd. is a clinical-stage specialty pharmaceutical company led by an experienced team of senior executives and scientists. Our goal is to create and enhance a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this in mind, the Company is currently engaged in the following drug development programs based on THC and / or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Gilles de la Tourette syndrome, for the treatment of Obstructive Sleep Apnea and Alzheimer’s Disease and Restlessness; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorders and epilepsy.

Forward-looking statements:

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other United States federal securities laws. For example, SciSparc uses forward-looking statements when discussing the expected medical benefits of its therapeutic products and drug candidates, the expected benefits of becoming a Nasdaq listed company. Since these statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and the actual results, performance or achievements of SciSparc could differ materially from those described or implied by the statements contained in this press release. Forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s annual report on Form 20-F filed with the Securities and Exchange Commission of the United States (the “SEC”) on March 30, 2021, and in subsequent filings with the SEC. Unless otherwise provided by law, SciSparc disclaims any intention or obligation to update or revise forward-looking statements, which are only valid on the date on which they were made, whether as a result of new information, future events or circumstances or otherwise.

Logo – https://mma.prnewswire.com/media/1434686/SciSparc_Ltd_Logo.jpg

Investor contact:
[email protected]
Phone. : + 972-3-6167055

SOURCE SciSparc Ltd.